Public health in the genomic era: Will Public Health Genomics contribute to major changes in the prevention of common diseases?

Archives of Public Health

Volumn 69, Issue 1, 2011, Pages 1-12

  Cleeren, Evy ^a,b   Van der Heyden, Johan ^a   Brand, Angela ^b   Van Oyen, Herman ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Epidemiology; Epigenomics; Genomics; Personalised healthcare; Policymaking; Prevention; Public health; Public health genomics; Translational research

Indexed keywords

EID: 84856786644     PISSN: 07787367     EISSN: None     Source Type: Journal    
DOI: 10.1186/0778-7367-69-8     Document Type: Article

References (69)

1. Via M, Gignoux C, Burchard E: The 1000 Genomes Project: new opportunities for research and social challenges. Genome Medicine 2010, 2(1):3.
2. Brand A: Integrative genomics, personal-genome tests and personalized healthcare: the future is being built today. Eur J Hum Genet 2009, 17(8):977-978.
3. Institute of Medicine (IOM): Genes, behavior and the social environment: moving beyond the nature/nurture debate. Washington DC: National Academies Press; 2006.
4. Beskow LM, Khoury MJ, Baker TG, Thrasher JF: The Integration of Genomics into Public Health Research, Policy and Practice in the United States. Community Genet 2001, 4(1):2-11.
5. Brand A, Brand H, Schulte in den Baumen T: The impact of genetics and genomics on public health. Eur J Hum Genet 2008, 16(1):5-13.
6. Genome-based Research and Population Health: Report of an expert workshop held at the Rockefeller Foundation Study and Conference Centre Bellagio, Italy, 14-20 April. 2005..
7. Burke W, Khoury MJ, Stewart A, Zimmern RL: The path from genomebased research to population health: development of an international public health genomics network. Genet Med 2006, 8(7):451-458.
8. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L: The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007, 9(10):665-674
9. Janssens AC, Van Duijn CM: Towards predictive genetic testing of complex diseases. Eur J Epidemiol 2006, 21(12):869-870.
10. Khoury MJ, Dorman JS: The Human Genome Epidemiology Network. Am J Epidemiol 1998, 148(1):4.
11. Smith GD, Gwinn M, Ebrahim S, Palmer LJ, Khoury MJ: Make it HuGE: human genome epidemiology reviews, population health, and the IJE. Int J Epidemiol 2006, 35(3):507-510.
12. Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ: A navigator for human genome epidemiology. Nat Genet 2008, 40(2):124-125.
13. Hunter DJ, Khoury MJ, Drazen JM: Letting the genome out of the bottle- will we get our wish? N Engl J Med 2008, 358(2):105-107
14. Rosenkotter N, Vondeling H, Blancquaert I, Mekel OC, Kristensen FB, Brand A: The contribution of health technology assessment, health needs assessment, and health impact assessment to the assessment and translation of technologies in the field of public health genomics. Public Health Genomics 2011, 14(1):43-52.
15. Becla L, Lunshof JE, Gurwitz D, Schulte In den BT, Westerhoff HV, Lange BM, et al: Health technology assessment in the era of personalized health care. Int J Technol Assess Health Care 2011, 27(2):118-126.
16. Retel VP, Bueno-de-Mesquita JM, Hummel MJ, van de Vijver MJ, Douma KF, Karsenberg K, et al: Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics. Int J Technol Assess Health Care 2009, 25(1):73-83.
17. Agurs-Collins T, Khoury MJ, Simon-Morton D, Olster DH, Harris JR, Milner JA: Public health genomics: translating obesity genomics research into population health benefits. Obesity (Silver Spring) 2008, 16(Suppl 3): S85-S94.
18. Smith GD, Ebrahim S, Lewis S, Hansell AL, Palmer LJ, Burton PR: Genetic epidemiology and public health: hope, hype, and future prospects. Lancet 2005, 366(9495):1484-1498.
19. Pearson TA, Manolio TA: How to interpret a genome-wide association study. JAMA 2008, 299(11):1335-1344.
20. Cornelis MC, Agrawal A, Cole JW, Hansel NN, Barnes KC, Beaty TH, et al: The gene, environment association studies consortium (GENEVA): maximizing the knowledge obtained from GWAS by collaboration across studies of multiple conditions. Genet Epidemiol 2010.
21. Villanueva CM, Silverman DT, Malats N, Tardon A, Garcia-Closas R, Serra C, et al: Determinants of quality of interview and impact on risk estimates in a case-control study of bladder cancer. Am J Epidemiol 2009, 170(2):237-243.
22. Khoury MJ, Mensah GA: Genomics and the prevention and control of common chronic disease emerging priorities for public health action. Prev Chronic Dis 2005, 2(2):A05.
23. Asthma genomics: implications for public health. University of Washington, Center of genomics and public health; 2004.
24. Public health genomics: The role of the Public Health Observatories. North East Public Health Observatory (NEPHO); 2008.
25. Khoury MJ, Gwinn M, Burke W, Bowen S, Zimmern R: Will genomics widen or help heal the schism between medicine and public health? Am J Prev Med 2007, 33(4):310-317
26. Brand AM, Probst-Hensch NM: Biobanking for epidemiological research and public health. Pathobiology 2007, 74(4):227-238.
27. Wright AF, Carothers AD, Campbell H: Gene-environment interactions-the BioBank UK study. Pharmacogenomics J 2002, 2(2):75-82.
28. Hakonarson H, Gulcher JR, Stefansson K: deCODE genetics, Inc. Pharmacogenomics 2003, 4(2):209-215.
29. Zika E, Schulte in den Baumen T, Kaye J, Brand A, Ibarreta D: Sample, data use and protection in biobanking in Europe: legal issues. Pharmacogenomics 2008, 9(6):773-781.
30. Hardelid P, Dezateux C: Neonatal screening for inborn errors of metabolism. Lancet 2005, 365(9478):2176.
31. Wang L, McLeod HL, Weinshilboum RM: Genomics and drug response. N Engl J Med 2011, 364(12):1144-1153.
32. Fackler JL, McGuire AL: Paving the Way to Personalized Genomic Medicine: Steps to Successful Implementation. Curr Pharmacogenomics Person Med 2009, 7(2):125-132.
33. Longo R, D'Andrea M, Sarmiento R, Gasparini G: Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab. Expert Opin Investig Drugs 2010, 19(Suppl 1):S41-S50.
34. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, et al: Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008, 358(10):999-1008.
35. PricewaterhouseCoopers: The new science of personalized medicine: translating the promise into practice. 2009.
36. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117-1130.
37. Panchal S, Bordeleau L, Poll A, Llacuachaqui M, Shachar O, Ainsworth P, et al: Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families? Clin Genet 2009
38. Narod SA, Foulkes WD: BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004, 4(9):665-676.
39. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009.
40. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536.
41. Cecile A, Janssens JW: Is the time right for translation research in genomics? Eur J Epidemiol 2008, 23(11):707-710
42. Feero WG, Guttmacher AE, Collins FS: The genome gets personal-almost. JAMA 2008, 299(11):1351-1352.
43. Seshadri S, Drachman DA, Lippa CF: Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. Arch Neurol 1995, 52(11):1074-1079.
44. Rockhill B: Theorizing about causes at the individual level while estimating effects at the population level: implications for prevention. Epidemiol 2005, 16(1):124-129.
45. Khoury MJ, Bowen MS, Burke W, Coates RJ, Dowling NF, Evans JP, et al: Current priorities for public health practice in addressing the role of human genomics in improving population health. Am J Prev Med 2011, 40(4):486-493.
46. Samet JM: The health benefits of smoking cessation. Med Clin North Am 1992, 76(2):399-414.
47. Carlsten C, Burke W: Potential for genetics to promote public health: genetics research on smoking suggests caution about expectations. JAMA 2006, 296(20):2480-2482.
48. Berrettini WH, Lerman CE: Pharmacotherapy and pharmacogenetics of nicotine dependence. Am J Psychiatry 2005, 162(8):1441-1451.
49. Rose G: Sick individuals and sick populations. Int J Epidemiol 1985, 14:32-38.
50. Evans JP: Health care in the age of genetic medicine. JAMA 2007, 298(22):2670-2672.
51. Brand A, Brand H: Public health genomics - relevance of genomics for individual health information management, health policy development and effective health services. IJPH 2006, 3(3-4):24-34.
52. Public Health Genomics European Network: final report. 2009.
53. Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile JF, Newport M, et al: Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996, 335(26):1956-1961.
54. Zimmern R, Stewart A: Public health genomics: origins and basic concepts. IJPH 2006, 3(3-4):9-15.
55. Khoury MJ: Interview: Dr. Muin J. Khoury Discusses the future of public health genomics and why it matters for personalized medicine and global health. Current Pharmacogenomics and Personalized Medicine 2009, 7:158-163.
56. Schröder P: Why genomics will not revolutionise public health. IJPH 2006, 3(3-4):16-19.
57. Kaye J, Boddington P, de VJ, Hawkins N, Melham K: Ethical implications of the use of whole genome methods in medical research. Eur J Hum Genet 2010, 18(4):398-403.
58. McGuire AL, Caulfield T, Cho MK: Research ethics and the challenge of whole-genome sequencing. Nat Rev Genet 2008, 9(2):152-156.
59. Knoppers BM, Leroux T, Doucet H, Godard B, Laberge C, Stanton-Jean M, et al: Framing genomics, public health research and policy: points to consider. Public Health Genomics 2010, 13(4):224-234.
60. Prainsack B, Reardon J, Hindmarsh R, Gottweis H, Naue U, Lunshof JE: Personal genomes: Misdirected precaution. Nature 2008, 456(7218):34-35.
61. Gurwitz D, Fortier I, Lunshof JE, Knoppers BM: Research ethics. Children and population biobanks. Science 2009, 325(5942):818-819.
62. Brand A: Public health and genetics-a dangerous combination? Eur J Public Health 2005, 15(2):114-116
63. Clayton EW: Ethical, legal, and social implications of genomic medicine. N Engl J Med 2003, 349(6):562-569.
64. Zimmern R, the Belgian NTF, Cassiman JJ, Gurwitz D, Ibarreta D, Lavinha J, Patch C, Riccardia W, Sasiadek M, Schröder-Bäck P, ten Kate L: Policy development for the timely and correct introduction of genome-based knowledge in health services. Document PHGEN I Working group VII 2009.
65. Scheuner MT, Sieverding P, Shekelle PG: Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 2008, 299(11):1320-1334.
66. Institute of Medicine (IOM): Who will keep the public healthy? Educating public health professionals for the 21st century Bethesda (MD): National Academies Press; 2003
67. Yearley S: The ethical landscapeidentifying the right way to think about the ethical and societal aspects of synthetic biology research and products. J R Soc Interface 2009, 6(Suppl 4):S559-S564.
68. Thomas JC, Irwin DE, Zuiker ES, Millikan RC: Genomics and the public health code of ethics. Am J Public Health 2005, 95(12):2139-2143.
69. Cho MK, Magnus D, Caplan AL, McGee D: Policy forum: genetics. Ethical considerations in synthesizing a minimal genome. Science 1999, 286(5447):2087-2090.